Factors such as rising prevalence of chronic diseases, growth in the biologics market, funding initiatives for drug delivery research, and technological advancements are driving the growth of this market.
The North American Drug Delivery Technologies Market is projected to reach USD 758.7 Billion by 2021 from USD 520.0 Billion in 2016, at a CAGR of 6.5%.
Download PDF Brochure: –https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1209
In this report, the North American drug delivery technologies market is segmented on the basis of route of administration, end user, and region. Based on end user, the market is segmented into hospitals, ambulatory surgical centers (ASCs)/clinics, home care settings, and other end users. The home care settings segment is expected to register the highest CAGR during the forecast period. Improving patient acceptability, patient awareness, and the need for comfortable usability have increased the use of drug delivery systems in home care settings, thus contributing to the growth of this end-user segment.
Based on route of administration, the North American drug delivery technologies market is segmented into oral, pulmonary, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. The topical drug delivery market is expected to grow at the highest CAGR during the forecast period.
The North American drug delivery technologies market is divided into two country-level segments, namely, the U.S. and Canada. The U.S. is expected to continue to dominate the market during the forecast period.
Speak To Analyst: – https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=1209
Johnson & Johnson, Inc. (U.S.), Novartis AG (Switzerland), F. Hoffman-La-Roche Ltd. (Switzerland), Bayer AG (Germany), Pfizer, Inc. (U.S.), 3M Company (U.S.), Becton, Dickinson and Company (U.S.), Merck & Co, Inc. (U.S.), Sanofi (France), Antares Pharma, Inc. (U.S.), and GlaxoSmithKline Plc. (U.K.) are some of the prominent players in the North American drug delivery technologies market.
